Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 09/28/23 | S-1/A | General form of registration statement for all companies including face-amount certificate companies |
|
75 | |
| 09/26/23 | UPLOAD | SEC-generated letter |
|
1 | |
| 09/19/23 | S-1 | General form of registration statement for all companies including face-amount certificate companies |
|
21 | |
| 09/19/23 | 8-K | Current report filing |
|
   |
3 |
| 09/07/23 | 3 | Initial statement of beneficial ownership of securities |
|
1 | |
| 09/01/23 | 8-K | Current report filing |
|
|
3 |
| 08/31/23 | 8-K | Current report filing |
|
|
3 |
| 08/22/23 | 8-K | Current report filing |
|
|
3 |
| 08/22/23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
2 | |
| 08/21/23 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
6 |
